Stock Market Prediction Based on Stock Prediction Algorithm: Returns up to 16.77% in 7 Days

BioTech Stocks Package Name: BioTech Stocks
Recommended Positions: Long
Forecast Length: 7 Days (06/28/2017 - 07/05/2017)
I Know First Average: 4.91%

Read The Full Forecast

Stock Market Prediction Algorithm

Biotech Stocks To Buy Based on Data Mining: Returns up to 12.20% in 3 Days

BioTech Stocks Package Name: BioTech Stocks
Recommended Positions: Long
Forecast Length: 3 Days (07/02/2017 - 07/05/2017)
I Know First Average: 4.15%

Read The Full Forecast

Biotech Stocks To Buy

Stock Algorithm Based on Artificial Intelligence: Returns up to 22.87% in 14 Days

52 Week Low Stocks Package Name: 52 Week Low Stocks
Recommended Positions: Long
Forecast Length: 14 Days (06/20/2017 - 07/04/2017)
I Know First Average: 5.39%

Read The Full Forecast

Stock Algorithm

Bright Path Ahead for Gilead Sciences: Algorithmic Forecast

This article was written by Cole Winston, a Financial Analyst at I Know First.

 Bright Path Ahead for Gilead Sciences

Summary
  • Governance
  • Business and Financial Performance
  • Price Action: Ending Bearish Sentiment
  • Bullish Forecast for GILD

Tesla Stock PredictionRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content Here

Gilead Stock Forecast: Biotech for the Market Win

GinaGina Guinasso is a Financial Analyst at I Know First. She graduated from Arizona State University with a bachelor's degree in Real Estate and University of San Francisco with a Master of Science in Financial Analysis.

Considering Gilead’s strong financial situation and their focus on business growth, research and development, and reaching more patients globally, this article takes a deeper look at why the I Know First’s algorithms predicted a strong buy.

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content Here

Stock Predictor Based On Algorithm: Up To 5.51% Return In 7 Days

Package Name:  S&P100 Stocks
Forecast Length: 7 Days (03/29/2016 – 04/05/2016)
I Know First Average: 2.54%

Read The Full Forecast

Stock Predictor

Gilead Stock Forecast: Can Pricing Pressure and Competition Stop Gilead’s 5-year Bull Run?

reuben 2Reuben Bor is a Financial Analyst Intern at I Know First
  • Gilead Sciences has returned over 330% to shareholders in the past 5 years
  • Merck has released a rival Hepatitis C drug that is substantially cheaper than Gilead’s Harvoni
  • Massachusetts’s Attorney General has threatened the company with legal action concerning the company’s pricing policies
  • Gilead Stock 2016 Outlook
GILD stock analysis

premiumRead The Full Premium Article

Subscribe to our exclusive content in the PREMIUM section